Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

VYGR

+ Watchlist+ Portfolio

Voyager Therapeutics, Inc.

Regulated industryDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.52
52-Week Range
$1.48 – $5.48
Market Cap
$103.92M
P/E (TTM)
—
EPS (TTM)
-1.74
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.77
PEG Ratio
—
Return on Equity
-58.90%
Return on Assets
-29.42%
Gross Margin
0.00%
Operating Margin
-436.18%
Profit Margin
0.00%
Current Ratio
6.81
Debt/Equity
0.23
Total Debt
$30.51M
Free Cash Flow
$-68.50M
Revenue Growth
-70.00%
Earnings Growth
—
Enterprise Value
$27.62M

Market Snapshot

About

Voyager Therapeutics is a clinical-stage gene therapy company developing treatments for severe neurological diseases. The company focuses on leveraging advanced adeno-associated virus (AAV) capsids and payloads to deliver transformative therapies for conditions including Parkinson disease, Alzheimer disease, and other central nervous system disorders.